Targeted metabolomics-based understanding of the sleep disturbances in drug-naive patients with schizophrenia.

ABSTRACT:

Background

Sleep disturbances are a common occurrence in patients with schizophrenia, yet the underlying pathogenesis remain poorly understood. Here, we performed a targeted metabolomics-based approach to explore the potential biological mechanisms contributing to sleep disturbances in schizophrenia.

Methods

Plasma samples from 59 drug-naïve patients with schizophrenia and 36 healthy controls were subjected to liquid chromatography-mass spectrometry (LC-MS) targeted metabolomics analysis, allowing for the quantification and profiling of 271 metabolites. Sleep quality and clinical symptoms were assessed using the Pittsburgh Sleep Quality Index (PSQI) and the Positive and Negative Symptom Scale (PANSS), respectively. Partial correlation analysis and orthogonal partial least sq

SUBMITTER: Yan H 

PROVIDER: S-EPMC11089724 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature